Recruiting
Phase 2

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Sponsor:

Oana Danciu

Code:

NCT05467891

Conditions

Locoregional Recurrence

Hormone Receptor-positive Breast Cancer

HER2-negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ribociclib

Fulvestrant

Anastrozole

Letrozole

Exemestane

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information